Blog
July 2021
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
Achieve Life Sciences has been awarded a grant from the National Institute on Drug Abuse (NIDA) of the National Institutes [...]
June 2021
Achieve Announces Completion of Enrollment in Phase 3 ORCA 2 Study
The Phase 3 ORCA-1 trial reaches target enrollment. ORCA-2 Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times [...]
April 2021
Achieve Life Sciences Hosts Virtual Non-Deal Roadshow
Achieve Life Sciences CEO John Bencich gave a corporate presentation at the company’s Virtual Non-Deal Roadshow on Tuesday, April [...]
A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial)
The ORCA-1 Phase 2b clinical trial of cytisinicline in adult smokers has been published in the journal Nicotine and [...]
Cytisinicline – the solution to stop smoking?
Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, discusses the need for vaping cessation therapies and the development of [...]
February 2021
Cytisinicline: A Treatment To Help People Battling Nicotine Addiction
President and CMO at Achieve Life Sciences, Dr. Cindy Jacobs, spoke with Technology Networks about the key challenges related [...]